Cancer and Pharmacology

Treatment often fails when cancer becomes resistant to anti-cancer drugs. Thus, drug resistance is a big challenge facing the survival of cancer patients. Research in discovering and designing drugs with new chemistry structure or mechanism of action is critical to overcome the drug resistance problem and give patient better chance to survive longer. Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to specifically bind to specific cells or proteins. Nanomedicine is the application of nanotechnology which made its debut with greatly increased possibilities in the field of medicine. Nanomedicine desires to deliver research tools and clinically reformative devices in the near future.The clinical toxicology importance of any drug interaction depends on factors that are drug-patient and administration related. Generally, a doubling or more in plasma drug concentration has the potential for enhanced adverse or beneficial drug response Drug interactions in oncology are of particular importance owing to the narrow therapeutic index and the inherent toxicity of anticancer agents. Interactions with other medications can cause small changes in the pharmacokinetics or pharmacodynamics of a chemotherapy agent that could significantly alter its efficacy or toxicity.

Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to specifically bind to specific cells or proteins. Functional genomics is a field of molecular biology that attempts to make use of the vast wealth of data produced by genomic and transcriptomic projects (such as genome sequencing projects and RNA-seq) to describe gene (and protein) functions and interactions. Novel drug delivery is the method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. From this, new ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy of drugs were generated. Nanomedicine is the application of nanotechnology which made its debut with greatly increased possibilities in the field of medicine. Nanomedicine desires to deliver research tools and clinically reformative devices in the near future. Pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body or on microorganisms or parasites within or on the body and the mechanisms of drug action and the relationship between drug concentration and effect.[ Consequently, a number of regulatory issues were discussed at the workshop, including regulatory oversight of the diagnostic tests used in clinical trials and trials focused on small subsets of cancer patients, as well as international differences in regulations and how to harmonize them. 

  • Therapeutic antibodies
  • Functional genomics
  • Novel drug delivery system
  • Cancer drug designing
  • Nanotechnology and nanomedicine
  • Pharmacodynamics and pharmacokinetics
  • Regulatory issues in cancer research

Related Conference of Cancer and Pharmacology

Cancer and Pharmacology Conference Speakers